Article
Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolaemia: An expert consensus statement from ERKNet and ESPN.
Atherosclerosis - 1 May 2024
Reijman M Doortje, Kusters D Meeike, Groothoff Jaap W, Arbeiter Klaus, Dann Eldad J, de Boer Lotte M, de Ferranti Sarah D, Gallo Antonio, Greber-Platzer Susanne, Hartz Jacob, Hudgins Lisa C, Ibarretxe Daiana, Kayikcioglu Meral, Klingel Reinhard, Kolovou Genovefa D, Oh Jun, Planken R Nils, Stefanutti Claudia, Taylan Christina, Wiegman Albert, Schmitt Claus Peter
Abstract excerpt
Homozygous familial hypercholesterolaemia is a life-threatening genetic condition, which causes extremely elevated LDL-C levels and atherosclerotic cardiovascular disease very early in life. It is vital to start effective lipid-lowering treatment from diagnosis onwards. Even with dietary and current multimodal pharmaceutical lipid-lowering therapies, LDL-C treatment goals cannot be achieved in many children....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
